Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients-Reference-Cited by-同舟云学术

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( MCL ) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Published:2020-04-17 Issue:6 Volume:95 Page:623-629
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Zhao Shuangtao¹,Kanagal‐Shamanna Rashmi²,Navsaria Lucy³,Ok Chi Young²^ORCID,Zhang Shaojun¹^ORCID,Nomie Krystle³,Han Guangchun¹,Hao Dapeng¹,Hill Holly A.³^ORCID,Jiang Changying³,Yao Yixin³,Nastoupil Loretta³,Westin Jason³,Fayad Luis³,Nair Ranjit³,Steiner Raphel³,Ahmed Sairah³,Samaniego Felipe³,Iyer Swaminathan P.³,Oriabure Onyeka³,Chen Wendy³,Song Xingzhi¹,Zhang Jianhua¹,Badillo Maria³,Moghrabi Omar³,Aranda Jorge³,Tang Guilin²^ORCID,Yin C. Cameron²^ORCID,Patel Keyur²,Medeiros Leonard Jeffrey²,Li Shaoying²^ORCID,Vega Francisco²,Thirumurthi Selvi⁴,Xu Guofan⁵,Neelapu Sattva³,Flowers Christopher R.³,Romaguera Jorge³,Fowler Nathan³,Wang Linghua¹,Wang Michael L.³^ORCID,Jain Preetesh³^ORCID

Affiliation:

1. Department of Genomic MedicineThe University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of HematopathologyThe University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Lymphoma and myelomaThe University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of GastroenterologyThe University of Texas MD Anderson Cancer Center Houston Texas USA

5. Department of Nuclear MedicineThe University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25796

Reference16 articles.

1. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

3. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

4. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

5. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China;Annals of Hematology;2024-01-02

2. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

3. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2023-10-25

4. A Push to Consider Mantle Cell Lymphoma in Adults with Leukemia/Lymphoma with Blastoid Morphology;Hematology Reports;2023-10-13

5. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers;Cancers;2023-10-12